SG Americas Securities LLC Has $510,000 Position in Ingevity Corporation $NGVT

Key Points

• SG Americas Securities LLC cut its stake in Ingevity by 61.0% in Q4, selling 13,475 shares and ending the quarter with 8,615 shares valued at $510,000.
• Ingevity missed Q4 estimates (EPS $0.58 vs. $0.74) and reported revenue down 3.2% year-over-year, but issued FY2026 guidance of 4.80–5.20 EPS versus analysts' average forecast of 4.45.
• Institutional investors own 91.59% of the stock, with large recent buys from UBS AM, Simcoe, Marshall Wace and new positions from Boston Partners and Arrowstreet, while analysts' consensus is a Hold with an $80 target.

SG Americas Securities LLC cut its stake in shares of Ingevity Corporation (NYSE:NGVT - Free Report) by 61.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 8,615 shares of the company's stock after selling 13,475 shares during the quarter. SG Americas Securities LLC's holdings in Ingevity were worth $510,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of NGVT. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Ingevity by 311.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 600,380 shares of the company's stock worth $23,769,000 after buying an additional 454,579 shares during the period. Simcoe Capital Management LLC lifted its holdings in Ingevity by 188.8% during the 2nd quarter. Simcoe Capital Management LLC now owns 624,935 shares of the company's stock worth $26,928,000 after buying an additional 408,508 shares during the period. Boston Partners acquired a new position in Ingevity during the 3rd quarter worth about $14,171,000. Marshall Wace LLP lifted its holdings in Ingevity by 217.4% during the 3rd quarter. Marshall Wace LLP now owns 228,201 shares of the company's stock worth $12,594,000 after buying an additional 156,301 shares during the period. Finally, Arrowstreet Capital Limited Partnership acquired a new position in Ingevity during the 3rd quarter worth about $8,571,000. 91.59% of the stock is owned by institutional investors and hedge funds.

Ingevity Stock Performance

Shares of Ingevity stock opened at $75.33 on Monday. Ingevity Corporation has a one year low of $30.19 and a one year high of $77.46. The firm has a market capitalization of $2.66 billion, a price-to-earnings ratio of -16.20 and a beta of 1.27. The business has a 50-day simple moving average of $70.35 and a 200 day simple moving average of $61.67. The company has a debt-to-equity ratio of 39.10, a current ratio of 1.33 and a quick ratio of 0.79.

Ingevity (NYSE:NGVT - Get Free Report) last issued its earnings results on Wednesday, February 25th. The company reported $0.58 EPS for the quarter, missing analysts' consensus estimates of $0.74 by ($0.16). Ingevity had a negative net margin of 13.51% and a positive return on equity of 126.25%. The firm had revenue of $255.10 million during the quarter, compared to the consensus estimate of $257.27 million. During the same period in the previous year, the firm earned $0.95 earnings per share. The business's quarterly revenue was down 3.2% on a year-over-year basis. Ingevity has set its FY 2026 guidance at 4.800-5.20 EPS. On average, research analysts anticipate that Ingevity Corporation will post 4.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on NGVT. BMO Capital Markets reissued an "outperform" rating and issued a $83.00 price objective on shares of Ingevity in a research report on Monday, March 2nd. Wall Street Zen lowered Ingevity from a "buy" rating to a "hold" rating in a research report on Saturday, April 4th. Zacks Research raised Ingevity to a "hold" rating in a research report on Tuesday, December 16th. Weiss Ratings reissued a "sell (d-)" rating on shares of Ingevity in a research report on Thursday, January 22nd. Finally, Wells Fargo & Company lifted their price objective on Ingevity from $65.00 to $75.00 and gave the stock an "equal weight" rating in a research report on Friday, February 27th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Ingevity presently has an average rating of "Hold" and a consensus target price of $80.00.

Ingevity Profile

Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.

The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.